Niclas Svedberg

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Long-Term Incidence of Atrial Fibrillation and Stroke Among Cross-Country Skiers

Niclas Svedberg, Johan Sundström, Stefan James et al. · Circulation · 2019 · 87 citations · Full text

Medicine, Cardiology, Sports Medicine +16

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Long-Term Incidence of Bradycardia and Pacemaker Implantations Among Cross-Country Skiers: A Cohort Study

Niclas Svedberg, Johan Sundström, Stefan James et al. · Circulation · 2024 · 10 citations

Medicine, Cardiology, Sports Medicine +16